ANDA 79025, held by Chartwell RX. Fosinopril Sodium; Hydrochlorothiazide.
As of Nov 21, 2026, ANDA 79025 (Fosinopril Sodium and Hydrochlorothiazide), held by Chartwell RX, was first approved by FDA on Sep 17, 2010, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 17, 2010 | Original application | Approved | None posted |
| Fosinopril Sodium and Hydrochlorothiazide10MG;12.5MG · tablet;oral | Fosinopril Sodium; Hydrochlorothiazide | Discontinued |
| Fosinopril Sodium and Hydrochlorothiazide20MG;12.5MG · tablet;oral | Fosinopril Sodium; Hydrochlorothiazide | Discontinued |
| Aug 20, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 3, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 17, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters